INX-315 — Investigational Agent
Other · Phase 1 · Incyclix Bio
Mechanism of Action
INX-315 is an orally bioavailable, selective CDK2 inhibitor designed to overcome CDK4/6 inhibitor resistance and to target CCNE1-amplified tumors by blocking cyclin E-CDK2 driven S-phase entry.
Investigational Indications
- CDK4/6 inhibitor-resistant HR+/HER2- metastatic breast cancer
- CCNE1-amplified solid tumors